

# Svetlana Lajic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4501305/publications.pdf>

Version: 2024-02-01

51  
papers

1,637  
citations

331670

21  
h-index

302126

39  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and Novel Treatment Strategies in Children with Congenital Adrenal Hyperplasia. <i>Hormone Research in Paediatrics</i> , 2023, 96, 560-572.	1.8	10
2	The impact of adherence and therapy regimens on quality of life in patients with congenital adrenal hyperplasia. <i>Clinical Endocrinology</i> , 2022, 96, 666-679.	2.4	5
3	Ambulatory Blood Pressure Monitoring in Children and Adults Prenatally Exposed to Dexamethasone Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2481-e2487.	3.6	6
4	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. <i>European Journal of Endocrinology</i> , 2022, 186, K17-K24.	3.7	7
5	Young adult Swedish patients with autoimmune Addison's disease report difficulties with executive functions in daily life despite overall good cognitive performance. <i>Psychoneuroendocrinology</i> , 2022, 140, 105714.	2.7	5
6	Changes in resting-state functional connectivity in patients with congenital adrenal hyperplasia. <i>NeuroImage: Clinical</i> , 2022, 35, 103081.	2.7	1
7	Long-Term Outcomes of Congenital Adrenal Hyperplasia. <i>Endocrinology and Metabolism</i> , 2022, 37, 587-598.	3.0	13
8	Assessment of medication adherence in children and adults with congenital adrenal hyperplasia and the impact of knowledge and self-management. <i>Clinical Endocrinology</i> , 2021, 94, 753-764.	2.4	6
9	Clinical outcomes in 21-hydroxylase deficiency. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 318-324.	2.3	10
10	Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. <i>Endocrine</i> , 2021, 71, 586-594.	2.3	31
11	Altered Gray Matter Structure and White Matter Microstructure in Patients with Congenital Adrenal Hyperplasia: Relevance for Working Memory Performance. <i>Cerebral Cortex</i> , 2020, 30, 2777-2788.	2.9	24
12	First Trimester DEX Treatment Is Not Associated with Altered Brain Activity During Working Memory Performance in Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4074-e4082.	3.6	10
13	The Success of a Screening Program Is Largely Dependent on Close Collaboration between the Laboratory and the Clinical Follow-Up of the Patients. <i>International Journal of Neonatal Screening</i> , 2020, 6, 68.	3.2	13
14	Update on the Swedish Newborn Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. <i>International Journal of Neonatal Screening</i> , 2020, 6, 71.	3.2	19
15	First-Trimester Prenatal Dexamethasone Treatment Is Associated With Alterations in Brain Structure at Adult Age. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2575-2586.	3.6	20
16	Good overall behavioural adjustment in children and adolescents with classic congenital adrenal hyperplasia. <i>Endocrine</i> , 2020, 68, 427-437.	2.3	10
17	Cognitive Function of Children and Adolescents With Congenital Adrenal Hyperplasia: Importance of Early Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e683-e691.	3.6	20
18	Perturbed Beta-Cell Function and Lipid Profile After Early Prenatal Dexamethasone Exposure in Individuals Without CAH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2439-e2448.	3.6	9

#	ARTICLE	IF	CITATIONS
19	Genome-wide investigation of DNA methylation in congenital adrenal hyperplasia. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 201, 105699.	2.5	1
20	Novel non-classic CYP21A2 variants, including combined alleles, identified in patients with congenital adrenal hyperplasia. <i>Clinical Biochemistry</i> , 2019, 73, 50-56.	1.9	2
21	21-Hydroxylase Deficiency: Clinical and Biochemical Aspects. , 2019, , 393-405.		0
22	Prenatal Diagnosis and Treatment of Congenital Adrenal Hyperplasia. , 2019, , 406-414.		0
23	Epigenetic Alterations Associated With Early Prenatal Dexamethasone Treatment. <i>Journal of the Endocrine Society</i> , 2019, 3, 250-263.	0.2	34
24	Evaluation of behavioral problems after prenatal dexamethasone treatment in Swedish children and adolescents at risk of congenital adrenal hyperplasia. <i>Hormones and Behavior</i> , 2018, 98, 219-224.	2.1	12
25	Prenatal dexamethasone treatment in the context of at risk CAH pregnancies: Long-term behavioral and cognitive outcome. <i>Psychoneuroendocrinology</i> , 2018, 91, 68-74.	2.7	22
26	Prenatal Treatment of Congenital Adrenal Hyperplasia: Long-Term Effects of Excess Glucocorticoid Exposure. <i>Hormone Research in Paediatrics</i> , 2018, 89, 362-371.	1.8	21
27	Cognitive impairment in adolescents and adults with congenital adrenal hyperplasia. <i>Clinical Endocrinology</i> , 2017, 87, 651-659.	2.4	46
28	Functional and Structural Consequences of Nine CYP21A2 Mutations Ranging from Very Mild to Severe Effects. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-10.	1.5	8
29	Sex-Dimorphic Effects of Prenatal Treatment With Dexamethasone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3838-3846.	3.6	56
30	In vitro functional studies of rare CYP21A2 mutations and establishment of an activity gradient for nonclassic mutations improve phenotype predictions in congenital adrenal hyperplasia. <i>Clinical Endocrinology</i> , 2015, 82, 37-44.	2.4	22
31	Prenatal Dexamethasone Treatment of Children at Risk for Congenital Adrenal Hyperplasia: The Swedish Experience and Standpoint. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1881-1883.	3.6	65
32	Functional studies of CYP21A2 mutants complement structural and clinical predictions of disease severity in CAH. <i>Clinical Endocrinology</i> , 2012, 76, 766-768.	2.4	4
33	Gender role behaviour in prenatally dexamethasone-treated children at risk for congenital adrenal hyperplasia – a pilot study. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2011, 100, e112-9.	1.5	44
34	Deficient cardiovascular stress reactivity predicts poor executive functions in adults with attention-deficit/hyperactivity disorder. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 63-73.	1.3	21
35	Long-Term Outcome of Prenatal Dexamethasone Treatment of 21-Hydroxylase Deficiency. <i>Endocrine Development</i> , 2011, 20, 96-105.	1.3	41
36	High self-perceived stress and many stressors, but normal diurnal cortisol rhythm, in adults with ADHD (attention-deficit/hyperactivity disorder). <i>Hormones and Behavior</i> , 2009, 55, 418-424.	2.1	98

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcome of Prenatal Treatment of Congenital Adrenal Hyperplasia. , 2008, 13, 82-98.		56
38	Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems?. European Journal of Endocrinology, 2008, 159, 309-316.	3.7	91
39	Cognitive Functions in Children at Risk for Congenital Adrenal Hyperplasia Treated Prenatally with Dexamethasone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 542-548.	3.6	202
40	Assisted large fragment insertion by Red/ET-recombination (ALFIRE)â€”an alternative and enhanced method for large fragment recombineering. Nucleic Acids Research, 2007, 35, e78.	14.5	48
41	Characterization of novel missense mutations in CYP21 causing congenital adrenal hyperplasia. Journal of Molecular Medicine, 2007, 85, 247-255.	3.9	27
42	Not All Amino Acid Substitutions of the Common Cluster E6 Mutation in CYP21 Cause Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2148-2153.	3.6	21
43	Prenatal treatment of congenital adrenal hyperplasia. European Journal of Endocrinology, 2004, 151 Suppl 3, U63-U69.	3.7	56
44	Novel Mutations in CYP21 Detected in Individuals with Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2824-2829.	3.6	48
45	CYP21 mutations in simple virilizing congenital adrenal hyperplasia. Journal of Molecular Medicine, 2001, 79, 581-586.	3.9	20
46	Effects of Missense Mutations and Deletions on Membrane Anchoring and Enzyme Function of Human Steroid 21-Hydroxylase (P450c21). Biochemical and Biophysical Research Communications, 1999, 257, 384-390.	2.1	14
47	Long-Term Somatic Follow-Up of Prenatally Treated Children with Congenital Adrenal Hyperplasia <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3872-3880.	3.6	137
48	Naturally Occurring Mutants of Human Steroid 21-Hydroxylase (P450c21) Pinpoint Residues Important for Enzyme Activity and Stability. Journal of Biological Chemistry, 1998, 273, 6163-6165.	3.4	43
49	Synergistic Effect of Partially Inactivating Mutations in Steroid 21-Hydroxylase Deficiency <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 194-199.	3.6	53
50	A cluster of missense mutations at Arg356 of human steroid 21-hydroxylase may impair redox partner interaction. Human Genetics, 1997, 99, 704-709.	3.8	61
51	An intron 1 splice mutation and a nonsense mutation (W23X) in CYP21 causing severe congenital adrenal hyperplasia. Human Genetics, 1996, 98, 182-184.	3.8	36